PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
32.96%
Revenue growth above 1.5x CVE's 5.97%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
39.42%
Gross profit growth at 75-90% of CVE's 45.55%. Bill Ackman would demand operational improvements to match competitor gains.
855.56%
EBIT growth above 1.5x CVE's 89.29%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
855.56%
Operating income growth above 1.5x CVE's 89.29%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
146.22%
Net income growth under 50% of CVE's 525.86%. Michael Burry would suspect the firm is falling well behind a key competitor.
147.06%
EPS growth under 50% of CVE's 530.25%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
147.06%
Diluted EPS growth under 50% of CVE's 530.81%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.37%
Share count expansion well above CVE's 0.07%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.37%
Diluted share count expanding well above CVE's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
30.29%
Dividend growth above 1.5x CVE's 10.31%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
104.11%
Positive OCF growth while CVE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
269.41%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
8.50%
10Y revenue/share CAGR under 50% of CVE's 85.49%. Michael Burry would suspect a lasting competitive disadvantage.
-58.41%
Negative 5Y CAGR while CVE stands at 85.49%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
12.78%
3Y revenue/share CAGR under 50% of CVE's 40.27%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
5.78%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-47.84%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
48.03%
Positive 3Y OCF/share CAGR while CVE is negative. John Neff might see a big short-term edge in operational efficiency.
-34.62%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-87.79%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
47.77%
Below 50% of CVE's 423.31%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-24.78%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-77.31%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-69.25%
Negative 3Y equity/share growth while CVE is at 20.94%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
81.20%
Dividend/share CAGR of 81.20% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-82.78%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-65.53%
Negative near-term dividend growth while CVE invests at 33.21%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-19.48%
Firm’s AR is declining while CVE shows 34.15%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-24.60%
Inventory is declining while CVE stands at 26.85%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.32%
75-90% of CVE's 1.47%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-10.24%
We’re deleveraging while CVE stands at 12.77%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
We cut SG&A while CVE invests at 34.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.